




RealRate

PHARMACEUTICAL 2022

Concert Pharmaceuticals INC
Rank 263 of 471

CoNCERT



RealRate

The First AI Rating Agency

www.realrate.ai

The relative strengths and weaknesses of Concert Pharmaceuticals INC are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Concert Pharmaceuticals INC compared to the market average is the variable Liabilities, Current, increasing the Economic Capital Ratio by 26% points. The greatest weakness of Concert Pharmaceuticals INC is the variable Research and Development, reducing the Economic Capital Ratio by 28% points.

The company's Economic Capital Ratio, given in the ranking table, is 268%, being 6.8% points below the market average of 275%.

Input Variable	Value in 1000 USD
Assets, Current	150,329
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	16,120
Liabilities, Non-Current	21,505
Other Assets	9,745
Other Compr. Net Income	-18
Other Expenses	2,083
Other Liabilities	15,466
Other Net Income	-460
Other Revenues	32,578
Property and Equipment	5,242
Research and Development	87,555
Selling, General and Administrative Expense	22,531

Output Variable	Value in 1000 USD
Assets	165,316
Liabilities	53,091
Expenses	112,169
Revenues	32,578
Stockholders Equity	112,225
Net Income	-80,051
Comprehensive Net Income	-80,060
BaseVar	181,816
ECR before LimitedLiability	151%
Economic Capital Ratio	268%